Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: <i>In Vitro</i> Characterization Studies

<table>Response surface plots for the <i>A</i> and <i>B</i> on zeta potential (<svg height="15.25" id="M37" style="vertical-align:-3.276pt" version="1.1" viewbox="0 0 19.924999 15.25" width="19.924999" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><path d="M775 650l-6 -28q-60 -6 -81.5 -16t-61.5 -54l-175 -191l125 -243q30 -58 48.5 -71t82.5 -19l-5 -28h-275l7 28l35 4q31 4 37 12t-6 34l-108 216q-140 -165 -177 -219q-16 -22 -10.5 -30.5t41.5 -13.5l22 -3l-7 -28h-244l8 28q52 4 75 15.5t67 52.5q48 46 206 231
l-110 215q-26 51 -44 63t-72 17l6 28h250l-6 -28l-27 -4q-30 -5 -35 -10t3 -27q17 -43 95 -190q70 78 154 185q15 21 10 29.5t-33 12.5l-30 4l5 28h236z" id="x1D44B"></path></g>
<g transform="matrix(.012,-0,0,-.012,13.525,15.187)"><path d="M412 140l28 -9q0 -2 -35 -131h-373v23q112 112 161 170q59 70 92 127t33 115q0 63 -31 98t-86 35q-75 0 -137 -93l-22 20l57 81q55 59 135 59q69 0 118.5 -46.5t49.5 -122.5q0 -62 -29.5 -114t-102.5 -130l-141 -149h186q42 0 58.5 10.5t38.5 56.5z" id="x32"></path></g>
</svg>), where <i>A</i> PLGA concentration and <i>B</i> Eudragit RL100 concentration.</table>

Journal of Nanotechnology

fig2

Figure 2

Figure 2: Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: <i>In Vitro</i> Characterization Studies 

Journal of Nanotechnology

Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies

Figure 2